Jim Simons’s Neurogene NGNE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $875K | Buy |
43,400
+29,400
| +210% | +$569K | ﹤0.01% | 2336 |
|
|
2025
Q4 | $288K | Buy |
+14,000
| New | +$348K | ﹤0.01% | 2777 |
|
|
2024
Q4 | – | Sell |
-22,807
| Closed | -$957K | – | 3791 |
|
|
2024
Q3 | $957K | Sell |
22,807
-30,000
| -57% | -$1.16M | ﹤0.01% | 2471 |
|
|
2024
Q2 | $1.92M | Sell |
52,807
-5,900
| -10% | -$208K | ﹤0.01% | 1911 |
|
|
2024
Q1 | $2.99M | Buy |
58,707
+8,513
| +17% | +$284K | ﹤0.01% | 1771 |
|
|
2023
Q4 | $973K | Buy |
50,194
+9,332
| +23% | +$134K | ﹤0.01% | 2424 |
|
|
2023
Q3 | $646K | Sell |
40,862
-5,999
| -13% | -$88.6K | ﹤0.01% | 2594 |
|
|
2023
Q2 | $778K | Buy |
46,861
+1,130
| +2% | +$18.5K | ﹤0.01% | 2623 |
|
|
2023
Q1 | $640K | Sell |
45,731
-13,941
| -23% | -$163K | ﹤0.01% | 2747 |
|
|
2022
Q4 | $607K | Sell |
59,672
-12,431
| -17% | -$128K | ﹤0.01% | 2839 |
|
|
2022
Q3 | $923K | Sell |
72,103
-8,610
| -11% | -$176K | ﹤0.01% | 2548 |
|
|
2022
Q2 | $1.66M | Buy |
80,713
+17,265
| +27% | +$421K | ﹤0.01% | 2324 |
|
|
2022
Q1 | $2.39M | Buy |
63,448
+21,267
| +50% | +$1.24M | ﹤0.01% | 2104 |
|
|
2021
Q4 | $4.07M | Buy |
42,181
+4,336
| +11% | +$528K | 0.01% | 1655 |
|
|
2021
Q3 | $5.47M | Buy |
37,845
+9,045
| +31% | +$1.38M | 0.01% | 1411 |
|
|
2021
Q2 | $5.32M | Sell |
28,800
-2,097
| -7% | -$464K | 0.01% | 1598 |
|
|
2021
Q1 | $7.61M | Sell |
30,897
-7,238
| -19% | -$1.85M | 0.01% | 1371 |
|
|
2020
Q4 | $10.8M | Sell |
38,135
-3,722
| -9% | -$909K | 0.01% | 1113 |
|
|
2020
Q3 | $10M | Sell |
41,857
-10,158
| -20% | -$2.46M | 0.01% | 1134 |
|
|
2020
Q2 | $17.3M | Buy |
52,015
+9,660
| +23% | +$2.52M | 0.01% | 906 |
|
|
2020
Q1 | $9.64M | Buy |
42,355
+6,386
| +18% | +$1.31M | 0.01% | 1189 |
|
|
2019
Q4 | $8.86M | Sell |
35,969
-2,423
| -6% | -$241K | 0.01% | 1522 |
|
|
2019
Q3 | $2.19M | Buy |
38,392
+14,248
| +59% | +$869K | ﹤0.01% | 2234 |
|
|
2019
Q2 | $1.14M | Buy |
24,144
+5,035
| +26% | +$259K | ﹤0.01% | 2621 |
|
|
2019
Q1 | $1.03M | Buy |
19,109
+8,180
| +75% | +$413K | ﹤0.01% | 2656 |
|
|
2018
Q4 | $472K | Buy |
10,929
+3,547
| +48% | +$173K | ﹤0.01% | 2885 |
|
|
2018
Q3 | $433K | Buy |
7,382
+4,538
| +160% | +$268K | ﹤0.01% | 2898 |
|
|
2018
Q2 | $151K | Buy |
+2,844
| New | +$741K | ﹤0.01% | 3106 |
|
|
2018
Q1 | – | Sell |
-1,508
| Closed | -$355K | – | 3503 |
|
|
2017
Q4 | $355K | Buy |
+1,508
| New | +$353K | ﹤0.01% | 2973 |
|
Other funds holding NGNE
SB
RG
CC
RI
EC
BBA
TECP
Jim Simons's NGNE Position: Q1 2026 in Review
Jim Simons increased its Neurogene (NGNE) stake by 210% in Q1 2026, buying an estimated $569K and bringing the position to 43,400 shares worth $875K. The position accounts for ﹤0.01% of the portfolio, ranked #2336.
Jim Simons first reported a position in NGNE in Q4 2017 and has held it in 29 quarters since. The position peaked at $17.3M in Q2 2020. 96 funds tracked by Wall St. Rank hold NGNE as of Q1 2026.
- Jim Simons held 43,400 shares of Neurogene worth $875K as of Q1 2026.
- Jim Simons bought 29,400 Neurogene shares in Q1 2026, an estimated $569K.
- Neurogene made up ﹤0.01% of Jim Simons's portfolio in Q1 2026, its #2336 holding.
- Jim Simons first reported a position in Neurogene in Q4 2017 and has held it in 29 quarters since.
- Jim Simons's Neurogene position peaked at $17.3M in Q2 2020.
- 96 funds tracked by Wall St. Rank held Neurogene as of Q1 2026.
Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.